MET, a master gene sustaining "invasive growth," is a relevant target for cancer precision therapy. In the vast majority of tumors, wild-type MET behaves as a "stress-response" gene and relies on the ligand (HGF) to sustain cell "scattering," invasive growth and apoptosis protection (oncogene "expedience"). In this context, concomitant targeting of MET and HGF could be crucial to reach effective inhibition. To test this hypothesis, we combined an anti-MET antibody (MvDN30) inducing "shedding" (i.e., removal of MET from the cell surface), with a "decoy" (i.e., the soluble extracellular domain of the MET receptor) endowed with HGF-sequestering ability. To avoid antibody/decoy interaction-and subsequent neutralization-we identified a single aminoacid in the extracellular domain of MET-lysine 842-that is critical for MvDN30 binding and engineered the corresponding recombinant decoyMET (K842E). DecoyMET K842E retains the ability to bind HGF with high affinity and inhibits HGF-induced MET phosphorylation. In HGF-dependent cellular models, MvDN30 antibody and decoyMET K842E used in combination cooperate in restraining invasive growth, and synergize in blocking cancer cell "scattering." The antibody and the decoy unbridle apoptosis of colon cancer stem cells grown in vitro as spheroids. In a preclinical model, built by orthotopic transplantation of a human pancreatic carcinoma in SCID mice engineered to express human HGF, concomitant treatment with antibody and decoy significantly reduces metastatic spread. The data reported indicate that vertical targeting of the MET/HGF axis results in powerful inhibition of ligand-dependent MET activation, providing proof of concept in favor of combined target therapy of MET "expedience."
Introduction
Metastatic spreading is based on the ability of cancer cells to disrupt cell-to-cell interactions, migrate through the extracellular matrix as well as survive and proliferate in tissues other than their site of origin. The physiological counterpart of this complex program-known as "invasive growth"-is at the basis of embryogenesis and accounts for wound healing and organ regeneration during adult life. Invasive growth is tightly regulated by specific extracellular signals, one of which is hepatocyte growth factor (HGF), the ligand for the receptor encoded by MET oncogene. 1 In conditions of aberrant activation, HGF/MET signaling drives tumor onset, progression and metastasis in a broad spectrum of human malignancies. 2 In a minority of events, MET behaves as a "driver" oncogene and tumor cells are dependent on constitutive MET signaling for growth and survival ("MET addiction"). This condition relies on the presence of genetic lesions, mostly increased gene copy number 3, 4 or, less frequently, mutations 5 that result in constitutive ligand-independent receptor activation. In this context, treatment with MET inhibitors is highly effective, inducing block of cell proliferation and cell cycle arrest in vitro and inhibition of tumor growth in vivo. 6, 7 The co-expression of ligand and receptor within the same cell is another strategy exploited by cancer to achieve continuous MET activation, and has been described mainly in non-epithelial human cancers, such as osteosarcomas, 8 glioblastomas 9 and multiple myelomas. 10 In most cases, however, aberrant MET activation in tumors originates from receptor over-expression, due to transcriptional upregulation of the wild-type gene, triggering cancer cell sensitization to ligand stimulation. 11 In the latter case, MET signaling-which results in pro-invasive and antiapoptotic responses-is exploited by cancer cells as a strategy to bypass stress conditions and boosts the malignant phenotype ("MET expedience" 12 ). In the absence of specific genetic lesions, MET is not strictly necessary for tumor growth, but the presence of the ligand sustains receptor activation, enhancing the malignant phenotype. Finally, MET behaves as a functional marker of cancer "stem-progenitor" cells in glioblastomas, 13, 14 and supports the "stem" phenotype in colorectal and breast cancers. 15, 16 Moreover, it has been shown that stromal-derived HGF sustains the Wnt self-renewal pathway of colorectal cancer stem cells and promotes proliferation of colon cancer initiating cells, triggering resistance to antiepidermal growth factor receptor (EGFR) therapy. 17 A number of strategies targeting MET or HGF-either small molecule inhibitors, antibodies or recombinant proteins-have been designed and are currently under investigation. 18, 19 Among them, the MvDN30 antibody is a monovalent chimeric Fab fragment that binds to the extracellular domain of MET, inducing proteolytic cleavage ("shedding") of the receptor from the cell surface. 20 Decoy-MET is a recombinant soluble receptor encompassing the whole extracellular region of MET; it binds HGF with high affinity and inhibits ligand-driven biological activities in vitro and in vivo when expressed by lentiviral vector technology 21 or as Fc-fusion protein. 22, 23 MvDN30 and decoyMET, used in combination, would allow dual targeting of ligand and receptor, acting simultaneously on MET-expressing cancer cells and on HGF-secreting tumor stroma. We show that vertical inhibition of the MET/HGF axis effectively hinders tumor cell growth, motility and invasion in vitro and significantly reduces metastatic spreading in vivo, providing proof of concept for combined targeted therapy in a broad spectrum of cancers expressing wild-type MET.
Materials and Methods

Cell culture
A549 human lung adenocarcinoma cells, HPAF-II human pancreatic adenocarcinoma cells and U87-MG human glioblastoma cells were obtained from ATCC/LGC Standards S.r.l. (Sesto San Giovanni, Italy) and cultured as suggested by the supplier. Human metastatic colorectal cancer M049 spheroid cultures (courtesy of Carla Boccaccio, University of Torino) were maintained as described. 15 M049 threedimensional cultures were established by mechanical disaggregation of xenopatient tumors, embedded in Growth Factor Reduced Matrigel (Corning) and cultured as described 15 with the addiction of 2 mM N-acetyl-L-cysteine (Sigma). All cell cultures were tested for mycoplasma contamination.
Generation, expression and purification of mutated MET ectodomains cDNA sequences of human MET ectodomains (decoyMET) carrying single aminoacid substitutions were generated using the QuickChange II Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA). Engineered soluble receptors were produced by transient transfection of HEK-293T cells with pcDNA3.1 plasmids (Invitrogen Corporation, Camarillo, CA) expressing cDNAs encoding for wild-type decoyMET or decoyMET mutants, and purified from cell supernatants by affinity chromatography using HisTrap HP columns (GE Healthcare, Freiburg, Germany) according to manufacturer's instructions. Large-scale protein production and purification was performed by U-Protein Express BV (Utrecht, The Netherlands).
Generation of a tridimensional homology model
The homology model was built by alignment of MET IPT 3-4 domains (wild-type and mutated) with the crystal structure of the top scored homologous Plexin A1 domains 7-10, IPT3-IPT6 (PDB 5L7N) 24 using SWISS-MODEL software (www.swissmodel.expasy.org).
Immunoprecipitation assays
To analyze the interaction of wild-type decoyMET or decoy-MET mutants with anti-MET antibodies, comparable amounts of decoyMET proteins-obtained from cells supernatants as described above and normalized according to Western blot analysis-were incubated with DN30 or DO24 monoclonal antibodies 25 for 30 min at 48C. Antibody-decoyMET complexes were immunoprecipitated with Sepharose-Protein A (GE Healthcare Life Science) and revealed by Western blot using horseradish peroxidase (HRP)-conjugated streptactin (IBA, Goettingen, Germany). Signal was detected using ECL System (GE Healthcare). To analyze the interaction of wildtype decoyMET or decoyMET K842E with HGF, comparable amounts of decoyMET proteins, obtained and normalized as above, were mixed with 1 ml of supernatants from MDA-MBWhat's new? MET is a "master gene" that can make tumors more aggressive. This occurs when HGF-the specific ligand for MET receptor, produced by the tumor microenvironment-binds to the receptor expressed by cancer cells. In this study, the authors developed a new strategy to target both MET and HGF at the same time, using a monoclonal antibody and a decoy receptor. This combined approach hindered tumor growth and invasion in vitro, and reduced metastasis in vivo. These results provide proof of concept for targeted therapy in a broad spectrum of cancers expressing wild-type MET.
435 cells transduced with a Lentiviral vector expressing human HGF 26 or supernatants from untransduced cells. After 2 hrs incubation at 48C, the complexes were immunopreciptated with DO24 immobilized on Sepharose-Protein A and revealed by Western blot using the biotinylated anti-HGF antibody BAF294 (R&D Systems, Minneapolis, MN) followed by decoration with HRP-conjugated streptavidin (GE Healthcare). Signal was detected using ECL System (GE Healthcare).
MET phosphorylation assay
Serum-starved A549 cells were incubated for 24 hrs with 125 nM MvDN30 or 2 mM decoyMET K842E , alone or in combination, and then stimulated with 50 ng/ml HGF (R&D Systems) for 2 hrs at 48C. Total cellular lysates were analyzed by Western blot using the following primary antibodies: anti-MET phospho-Tyr 1234/1235 (D26, Cell Signaling Technology, Beverly, MA); anti-MET (3D4, Invitrogen Corporation) and anti-vinculin (clone hVIN-1, Sigma, Saint Louis, MO). Secondary HRP-conjugated anti-mouse or anti-rabbit IgGs were from Jackson Immuno Research (West Grove, PA). Western blot bands were quantified with ImageJ software. Phospho-MET signal was normalized on vinculin (loading control). Values obtained were converted in logarithmic form, control (HGF-treated sample) subtracted and represented with heatmaps generated by the freeware Gedas program. 27 
Phosphorylation of downstream transducers
Serum-starved A549 cells were incubated for 24 hrs with 500 nM MvDN30 or 2 mM decoyMETK842E, alone or in combination, and then stimulated with 100 ng/ml HGF (R&D Systems) for 15 min at 378C. Total cellular lysates were analyzed by Western blot using the following primary antibodies: anti-ERK phospho-Thr202/Tyr204 (Cell Signaling Technology); anti-ERK (Cell Signaling Technology); anti-AKT phospho-Ser473 (Cell Signaling Technology); anti-AKT (Cell Signaling Technology); anti-GAPDH (D4C6R, Cell Signaling Technology). Secondary HRP-conjugated anti-mouse or anti-rabbit IgGs were from Jackson Immuno Research. Western blot bands were quantified with ImageJ software. PhosphoERK and phosphoAKT were normalized on the corresponding total proteins. Heatmaps were generated as described above.
ELISA binding assays
For analysis of the interaction between decoyMET and the DN30 or DO24 mAbs, affinity-purified soluble receptors (wild-type decoyMET or decoyMET K842E , 100 ng/well) were immobilized on enzyme-linked immunosorbent assay (ELISA) plates and increasing concentrations of the antibodies (0-100 nM) were added in liquid phase. Binding was revealed using HRP-conjugated anti-mouse antibodies (GE Healthcare). For analysis of decoyMET binding to HGF, soluble receptors (50 ng/well) were immobilized on ELISA plates pre-coated with the DO24 antibody (100 ng/well) and incubated with increasing concentrations of HGF (0-10 nM) in solution.
Binding was detected using the anti-HGF biotinylated antibody BAF294 (R&D Systems) and revealed with HRP-conjugated streptavidin (GE Healthcare). Colorimetric assay was quantified by the multi-label plate reader VICTOR-X4 (Perkin Elmer Instruments INC., Whaltman, MA). Data were analyzed and fit using Prism software (GraphPad).
In vitro biological assays
For anchorage-independent growth assays, cells were suspended in the appropriate culture medium supplemented with 2% fetal bovine serum (FBS) and 0.5% Seaplaque agarose (BMA, Rockland, ME), and seeded in 48-well plates (500 cells per well) on top of 1% agarose. Fresh medium containing the treatments was supplied twice weekly. A549 cells were treated with 1 mM MvDN30 or 1 mM decoyMET K842E , alone or in combination, in the presence of 30 ng/ml HGF. U87-MG cells were treated with 0.5 mM MvDN30 or 1 mM decoyMET K842E , alone or in combination. Colonies were stained with tetrazolium salts (Sigma) after 12 days of culture. Colony growth was determined using Metamorph software (Molecular Devices, Sunnyvale, CA). For cell invasion assays, HPAF-II cells (1.5 3 10 5 per well) were suspended in serum-free culture medium in the presence of 0.5 mM MvDN30 or 1 mM decoyMET K842E , alone or in combination, and seeded on the upper compartment of transwell chambers pre-coated with 30 lg/well of Matrigel Matrix (Corning Incorporated, NY). Culture medium supplemented with 2% FBS and 12.5 ng/ml HGF was added to the lower compartment of the chamber. After 24 hrs, cells on the upper side of the transwell filters were mechanically removed, while cells migrated through the membrane were fixed with 11% glutaraldehyde and stained with 0.1% crystal violet. Cell invasion was quantified with Image-J software. For cell scattering assays, HPAF-II cells (8,000 cells per well) were seeded in 96-well plates in complete culture medium. After 6 hrs, increasing concentrations (0-4 mM) of MvDN30 or decoy-MET K842E , alone or in 1:1 combination, were added. After additional 24 hrs, cells were stimulated with 6.25 ng/ml HGF for 20 hrs. Cells were fixed with 11% glutaraldehyde and stained with 0.1% crystal violet (Sigma-Aldrich). For realtime cell motility assay, HPAF-II cells were seeded in Eplates (8,000 cells per well; Roche Diagnostics, Mannheim, Germany) and treated as above. Electrical impedance was monitored continuously for 48 hrs, with data recording every 10 min, using a X-Celligence RTCA device (Roche Diagnostic). Values are expressed as cell index normalized at the instant of HGF addition. For viability assays, spheroids were seeded in 96-well plates (1,000 per well) in stem cell medium in the presence of 20 ng/ml HGF. The following day, spheroids were treated with increasing concentrations of MvDN30 or decoyMET K842E (0-700 nM), either alone or in 1:1 combination. After 4 days of treatment, cell number was determined using CellTiter-Glo (Promega Corp., Madison, WI) with a VICTOR X4 multi-label plate reader (Perkin Elmer). Data were analyzed and fit using Prism software (GraphPad). For apoptosis assays, spheroids were seeded as above and treated with 77 nM MvDN30 and 25 nM decoy-MET K842E in the presence of 20 ng/ml HGF. Apoptosis was determined after 48 hrs by the free nucleosome method using a Cell Death Detection ELISA PLUS Kit (Roche diagnostics).
Immunofluorescence
Immunofluorescence analysis on tumor cells and tissues was performed as described. 28, 29 Staining was carried out with: anti-MET phospho-Tyr 1234/1235 primary antibody (D26) revealed by Alexa Fluor 555-conjugated secondary antibody; anti-E-cadherin primary antibody (EP700Y, Abcam, Cambridge, UK) revealed by Alexa Fluor 488-conjugated secondary antibody; anti-vimentin primary antibody (VIM 3B4, Merk. Vimodrone, Italy) revealed by Alexa Fluor 555-conjugated secondary antibody and anti-cleaved Caspase-3 (Asp175) primary antibody (Cell Signaling Technology) revealed by Alexa Fluor 488-conjugated secondary antibody. Cells were counterstained with 488-conjugated phalloidin (Molecular Probes). All images were captured with a Leica TCS SP5 AOBS confocal laser-scanning microscope (Leica Microsystems). Immunofluorescence acquisition settings were kept constant within each cell line or tumor tissue. Mean fluorescence intensity (MFI) was evaluated with ImageJ software, measuring the mean pixel intensity in each channel, background subtracted. MFI was normalized on phalloidin for cell lines and spheroids and on DAPI for tumors.
In vivo experiments
All animal procedures were performed according to protocols approved by Ethical Committee for animal experimentation of the Fondazione Piemontese per la Ricerca sul Cancro and by Italian Ministry of Health. NOD-SCID mice were purchased from Charles River (Calco, Italy); hHGF-Ki SCID mice were obtained from AVEO Pharmaceuticals, Cambridge, MA. U87-MG cells were injected subcutaneously (2 3 10 6 cell per mouse) in the right flank of female NOD-SCID mice. Tumor growth was monitored by caliper measurement twice weekly and tumor volume was calculated as described previously. 30 When the tumors reached a volume of 80-100 mm 3 (Day 0), mice were stratified in four homogeneous groups and treated twice weekly by intratumor injection with: vehicle (n 5 10); MvDN30, 12.5 mg (n 5 9); K842E, 125 mg (n 5 9) and the combination of the two (n 5 10). After 22 days of treatment, mice were sacrificed and tumors were excised and embedded in paraffin for histological analysis. Tumor volume fold increase is calculated as the ratio between the value at Day 22 and the one at Day 0. HPAF-II cells were transduced with 100 ng/ml p24 of lentiviral vectors carrying the luciferase gene under the control of the CMV promoter as described. 31 Luciferase-expressing HPAF-II cells (10 4 cells per mouse) were injected in the pancreas of 4-to 6-week-old female hHGF-Ki SCID mice. After 2 days, mice were injected intraperitoneally with XenoLight D-Luciferin (150 mg/kg; Perkin Elmer), stratified into homogeneous groups on the basis of the bioluminescence signal using an IVIS Spectrum CT apparatus (Perkin Elmer), and randomly assigned to four treatment arms: vehicle (n 5 10); MvDN30 (10 mg/kg, n 5 6); decoyMET K842E (10 mg/kg, n 5 6); MvDN30 1 decoyMET K842E (10 1 10 mg/kg, n 5 6). Treatments were administered daily (MvDN30) or every 2 days (decoyMET K842E ) by intraperitoneal injection. At sacrifice, after five weeks of treatment, tumors and lungs were excised. Tumors were embedded in paraffin or OCT and processed for immunohistochemical or immunofluorescence analysis, respectively. Proliferation of tumor cells was determined using a monoclonal anti-Ki67 antibody (MIB-1, Agilent Technologies) as described previously. 32 Lungs were processed for histochemical analysis and micrometastases were evaluated by light microscopy on paraffin-embedded, HEstained non-sequential sections. For each mouse, 10 slides were analyzed; metastatic lesions were scored and their area quantified with ImageJ software.
Statistical analysis
Average, standard deviation (SD) and standard error of the mean (SEM) were calculated using Microsoft Office Excel 2010 software (Microsoft Corporation, Redmond, Washington). To calculate K d values, data from ELISA assays were analyzed and fitted according to nonlinear regression, one site binding hyperbola curve, using GraphPad Prism software (GraphPad Software, San Diego, California). To calculate inhibitory concentration 50 (IC 50 ) values, data from proliferation assays were analyzed and fitted according to nonlinear regression, sigmoidal dose-response curve, using GraphPad Prism software. Statistical significance was determined using a two-tailed Student's t test. All experiments were repeated at least three times. The in vivo experiments were performed two times. Figures show one representative experiment.
Results
Site-directed mutagenesis of the DN30-binding epitope in decoyMET
To exploit the activity of MvDN30 antibody and decoyMET in combination, it is mandatory to prevent interaction between the two molecules, which would result in mutual neutralization. It has been shown previously that MvDN30 recognizes an epitope within the IPT-4 domain of MET extracellular region at the boundary with the IPT-3 domain. 33 Former studies showed that the parental DN30 antibody, that binds the human receptor with picomolar affinity, also interacts with dog and rat MET, 25, 34 while it does not cross-react with mouse. 20 Upon alignment of the IPT-3 and IPT-4 aminoacid sequences of the abovementioned mammalian species, a number of residues were identified that are selectively changed in the mouse (Fig. 1a) . To test whether human-tomouse swapping of single aminoacid residues could impair antibody binding, soluble receptors carrying point mutations in the IPT 3-4 domain were generated and tested against the DN30 antibody. Substitution of lysine 842 with glutamic acid Cancer Therapy and Prevention generated decoyMET K842E , a modified soluble receptor not recognized anymore by the antibody, while all other mutations did not affect the interaction (Fig. 1b) . This mutation did not disrupt the overall structure of the protein, in fact decoyMET K842E was immunoprecipitated by DO24, an antibody binding a different epitope in the extracellular region of MET 25 (Fig. 1c) . This result was confirmed in ELISA assays, performed with affinity-purified decoys in solid phase and antibodies in liquid phase (Fig. 1d ). The homology model of the IPT 3-4 domains shows that the residue at position 842 is exposed at the surface. The substitution of lysine with glutamic acid induces an evident structural modification, presumably resulting in critical perturbation of the binding site and thus hampering decoyMET K842E -antibody interaction (Fig. 1e) .
DecoyMET K842E binds HGF with high affinity
We then investigated whether the K842E amino acid substitution interferes with binding of HGF. In immunoprecipitation assays, the amount of HGF bound by decoyMET K842E was comparable or higher to the amount bound by wild-type decoyMET (Fig. 2a) . In ELISA binding assays, the affinity constant of decoyMET K842E for HGF (K d 5 1.04 6 0.05 nM) was superimposable with the K d of 1.44 6 0.07 nM measured for the wild-type decoyMET (Fig. 2b) . Finally, the inhibitory activity of decoyMET K842E was tested in an HGF-induced MET phosphorylation assay. As shown in Figure 2c , wild-type decoyMET and decoyMET K842E inhibited HGF-dependent MET phosphorylation in A549 lung cancer cells with comparable potency. Thus, the K842E substitution does not interfere with the formation of a stable complex with HGF, and leaves the inhibitory activity of the decoy unaffected.
MvDN30 and decoyMET K842E cooperate in inhibition of MET phosphorylation and downstream biological responses
To assess the inhibitory activity elicited by concomitant targeting of the ligand and the receptor on MET signal transduction, we tested MET phosphorylation in the presence of MvDN30 and decoyMET K842E , either alone or in combination. To this end A549 cells, expressing a wild-type MET receptor, were stimulated with nanomolar concentrations of HGF and MET activation measured by phosphoMET antibodies. Both molecules displayed inhibitory activity, and the combination of the two was more efficient (Fig. 3a) . Analysis of downstream signaling transducers confirmed that the combination achieved the most effective inhibition of ERK and AKT activation (Fig. 3b) . On the biological ground, MvDN30 and decoyMET
K842E
in combination strongly inhibited anchorage-independent colony growth in cellular models of either autocrine or paracrine HGF stimulation. In the former, U87-MG glioblastoma cells-displaying very efficient colony growth in soft agar due to a MET/HGF autocrine loop-were inhibited by 75% when MvDN30 and decoyMET K842E were used in combination, while colony growth inhibition never exceeded 40% when the two molecules were used as single agents (Fig. 3c) . Similarly, the combo treatment completely blocked the formation of A549 soft agar colonies induced by nanomolar concentrations of exogenously-administered HGF, while MvDN30 and decoyMET K842E alone achieved a partial although significant inhibition of colony growth (65% and 74%, respectively, Fig.  3d ). Similar results were obtained in invasion assays performed in Matrigel-coated chambers: MvDN30 and decoy-MET K842E in combination reduced HGF-driven invasion of HPAF-II human pancreatic adenocarcinoma cells by 85%, while as single agents achieved only 59% and 52% inhibition, respectively (Fig. 3e) . In all these biological systems, MvDN30 and decoyMET K842E combination impaired MET phosphorylation more efficaciously than the single treatments (Supporting Information Fig. S1 ).
To assess whether the effect of the two inhibitors is additive or synergistic, a quantitative motility assay was performed. HPAF-II human pancreatic adenocarcinoma cells, expressing wild-type MET, were induced to scatter by HGF. Cell scattering was quantified by measuring the variations in electrical impedance of cell-covered electrodes (X-CELLigence 
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Real Time Cell Analyzer). The two molecules in combination reduced HGF-dependent cell scattering in dose-dependent fashion, starting inhibition at 250 nM and achieving complete blockage in the micromolar range (Figs. 4a and 4b) . The cell index values measured at the end of the experiment (time 5 48 hrs) were normalized on HGF (Fig. 4c) and elaborated with the CalcuSYN software to assess synergism (Fig. 4d) : for all concentrations examined, the calculated Combination Index (CI) was well below 0.5 (CI 5 0.1, 0.09, 0.17 and 0.38 for 0.06, 0.25, 1 and 4 mM, respectively), indicating that MvDN30 and decoyMET K842E display a synergistic behavior.
35
MvDN30 and decoyMET K842E impair growth and survival of
Colon-derived spheroids
It has been reported that HGF-induced MET activation in colorectal cancer stem cells supports the stem phenotype. Moreover, microenvironmental growth factors-including HGF-play a role in reducing the sensitivity of cancerderived stem cells to targeted therapies. 36 Colon spheroidsenriched in cancer stem/progenitor cells expressing wild-type MET-were prepared from a patient-derived xenograft of colorectal cancer liver metastasis 15 and tested for growth or apoptosis in the presence of exogenous HGF. In the growth assay, the combination of MvDN30 and decoyMET K842E reached the inhibitory effect (IC 50 ) at concentrations six to eight times lower than the IC 50 obtained by single treatments (Fig. 5a ). In line with these results, treatment by either reagent alone was virtually ineffective in inducing programmed cell death at the dose tested, while a strong proapoptotic effect was generated by the concomitant administration of the two molecules (Fig. 5b) . Accordingly, the strongest inhibition of HGF-induced MET-phosphorylation was obtained by the combined treatment (Fig. 5c ).
MvDN30 and decoyMET
K842E attenuate the invasive phenotype and reduce metastatic spread
The inhibitory activity of MvDN30 and decoyMET K842E in combination was assessed in vivo in mouse models of liganddriven MET stimulation.
The U87-MG glioblastoma xenograft tumor model of autocrine HGF stimulation was investigated. Cells were injected subcutaneously in NOD-SCID mice; when tumors reached a volume of 80-100 mm 3 , mice were stratified in homogeneous groups and randomly assigned to four treatment arms: Vehicle, MvDN30, decoyMET K842E or the combination of the two. After 22 days of treatment, mice were sacrificed and primary tumors excised for histological examination. While the combo treatment only marginally inhibited tumor growth, it reduced the phenotypic hallmarks of tumor invasion (Supporting Information Fig. S2 ).
The combo treatment was also challenged in a paracrine model of HGF stimulation. As previously reported, mouse HGF does not activate the human MET receptor. 37, 38 Hence, to test the inhibitory activity of decoyMET K842E in xenografts of human tumors, we exploited a transgenic SCID mouse where the mouse HGF gene was replaced by the human gene (hHGFKi). 39 Human pancreatic adenocarcinoma cells (HPAF-II) were labeled by transduction with the luciferase gene and injected orthotopically in the pancreas of hHGF-Ki mice. Engraftment was checked by analysis of total body luminescence; mice were stratified into homogeneous groups on the basis of bioluminescence values and randomly assigned to four treatment groups: VEHICLE, MvDN30, decoyMET K842E or the combination of the two. Tumor growth was monitored by total body luminescence (Supporting Information Fig. S3a ). At sacrifice, 5 weeks after cell injection, tumors were excised and analyzed for MET phosphorylation, proliferation, apoptosis and vimentin/E-cadherin expression (markers of epithelial-mesenchimal transition). 
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Concurrently, lungs were collected for histochemical evaluation of metastatic nodules. The phosphorylated status of MET at Tyrosines 1234-1235 was inhibited by either agents, and the combo treatment elicited a dramatic effect (Fig. 6a) . As expected in this model of MET oncogene "expedience" (i.e., expression of wild-type MET), proliferation as well as apoptosis were modestly affected, and only by the combo treatment (Supporting Information Figs. S3b and S3c). Analysis of the ratio between vimentin and E-cadherin showed that the combination treatment pushed cancer cells toward a more epithelial phenotype (Fig. 6b) . Accordingly, concomitant administration of MvDN30 and decoyMET K842E significantly inhibited METdriven metastatic dissemination to the lung (Fig. 6c) .
Discussion
Pharmacological inhibition of the MET tyrosine kinase receptor in oncogene "addicted" cancer cells extinguishes cell proliferation and invasion. Accordingly, patients with MET amplified advanced non-small cell lung cancer; metastatic gastric or esophageal cancer respond to anti-MET therapy. 40, 41 On the other hand, cancer cells without MET genetic alterations exploit the "physiological" program triggered by the oncogene as an "expedient" to boost the malignant phenotype. "Expedience" requires stimulation of wild-type MET by its ligand HGF. In this respect, the contribution of tumor microenvironment to cancer progression and metastasis is becoming increasingly relevant, as experimental evidences suggest that the malignant phenotype does not develop in a strictly cell-autonomous way, but in a rather complex interplay between cancer cells and host stroma. 42 The tumor microenvironment is a significant source of HGF, secreted by stromal cells of mesenchymal origin as an inactive precursor (proHGF). The latter is stored in the extracellular matrix, thanks to its avidity for heparansulfates, and is activated by specific proteases produced either by tumor or stromal cells. 43 Therefore, an excess of biologically active ligand is readily available for binding the MET receptor and triggers the invasive growth signaling cascade in "non-addicted" cells. This article shows that in conditions of MET "expedience," a concomitant intervention hitting both sides of the MET/HGF axis results in improved inhibitory activity. Simultaneous targeting was achieved combining a monovalent MET antibody, MvDN30, with a recombinant soluble receptor, decoy-MET K842E . The data provided herein indicate that there is no redundancy in targeting the same pathway with complementary tools. We selected the two inhibitors on the basis of their mechanisms of action. The antibody induces the physical removal of MET from the cell surface by "shedding" of the ectodomain; the latter is released in the extracellular environment and acts as "decoy" for HGF. Exogenous supply of 
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recombinant decoyMET reinforces the HGF-sequestering activity of the endogenous decoyMET generated by MvDN30. To enable the concomitant use of MvDN30 and decoyMET, a modified soluble receptor was generated (decoyMET K842E ), deficient in MvDN30 interaction but endowed with high affinity binding properties to HGF. The two agents in combination cooperate in a variety of cancer cells, reducing the effective therapeutic dose. Moreover, this "dual strategy" displays a strong synergistic effect, potentially exerting a superior anti-tumor efficacy. Interestingly, the combination of MvDN30 and decoyMET K842E impairs growth and survival of patient-derived colon cancer stem cells expressing MET. MET expression in a sub-population of stem/progenitor cancer cells has been defined as MET "inherence", 44 that is, the physiologic (inherent) HGF-induced intracellular response activated in cancer stem cells-in the absence of genetic lesions-responsible for resistance to targeted therapies, such as EGFR inhibitors in colorectal cancer. The notion linking cancer stem cells and resistance to conventional therapies is largely accepted, and the role of microenvironmental HGF in maintaining the stem phenotype of MET-expressing progenitor cells is becoming more and more established. An effective anti-MET treatment, as the combination of MvDN30 and decoyMET K842E , could represent a therapeutic support to blunt cancer stem cells and to oppose the onset of resistance to targeted therapies. On the other hand, in all cases where MET activation is ligand-independent-i.e., in the presence of activating mutations, occurring in solid tumors with a frequency of 1-2% (COSMIC database: www.sanger.ac.uk)-the vertical inhibition of the MET/HGF axis may be redundant.
The role of host microenvironment is difficult to investigate in mouse xenografts due to the limited cross-reactivity between murine stromal-derived factors and specific targets on human cancer cells. This is particularly significant in the case of the HGF/MET system, because murine HGF does not activate human MET. 37, 38 The development of genetically modified mouse strains expressing the knocked-in human HGF gene (hHGF-Ki mice) circumvented this problem. In this transgenic model, we show that concomitant targeting of environmental HGF and its receptor on cancer cells may be an effective therapeutic strategy to hinder malignant progression and metastasis.
Xenografts of pancreatic adenocarcinoma are characterized by precocious metastatic dissemination, occurring very early during tumor development and are sustained by an abundant stromal compartment. 45, 46 Recently, HGF secreted by pancreatic stellate cells was identified as a factor playing a relevant function in tumor-stroma interaction in this type of malignancy. 47 In an orthotopic mouse model of human pancreatic adenocarcinoma grafted in hHGF-Ki mice, MvDN30 and decoyMET K842E in combination slightly delayed tumor growth, as expected in a model of "expedience" where MET is not the driver oncogene. On the other hand, the combo treatment proved to be very effective in reducing the metastatic spread, suggesting a possible therapeutic application in non-addicted cancer cells featuring wild-type MET. Epidemiological data show that only 2-3% of epithelial cancers rely on MET oncogenic addiction, either because of gene amplification, rearrangement or mutation (COSMIC database: www.sanger.ac.uk). For this reason, a number of clinical trials-addressing unselected populations of cancer patients-failed. 48, 49 On the other hand, the vast majority of carcinomas exploit ligand-dependent wild-type MET activation to unleash the invasive metastatic phenotype in response to hypoxia, ionizing radiation or chemotherapy. [50] [51] [52] Thus, these findings suggest that a large cohort of patients-currently unfit to MET targeted therapy due to the absence of a specific genetic lesion-should benefit from treatments inspired by the dual antibody-decoy strategy, that allows optimal blockade of the HGF-driven MET signaling.
